top of page

Pre-clinical proof of concept and Clinical proof of concept (Phase I)


at a glance


Malaria (P. Falciparum)


01 November 2023 to 30 April 2028


European Vaccine Initiative


European Union


8.2 Mio Euro


Correlates of Protective immunity-driven investigation of malaria vaccine combination strategies

CAPTIVATE will develop a new and improved vaccine targeting multiple developmental stages of P. falciparum, the most dangerous form of the malaria parasite. The consortium will optimise the efficacy of current pre-erythrocytic vaccines while evaluating the safety and immunogenicity of new blood-stage mRNA vaccine candidates, from pre-clinical testing to an early-stage clinical trial.
In parallel, the consortium will work on developing the next generation of highly efficacious malaria vaccine candidates using an advanced in-silico platform to analyse TCR- and single cell sequencing data in combination with artificial intelligence (AI) based predictions of novel malaria vaccine antigens.
The consortium will also establish a European facility for production of malaria sporozoites for research and clinical use



CAPTIVATE Consortium is comprised with experts in the fields of malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses and innovative omics approaches:

-Deutsches Krebsforschungszentrum Heidelberg (Germany)
-European Vaccine Initiative (EVI) (Germany)
-Immunewatch (Belgium)
-Leiden University Medical Center (Netherlands)
-NEC OncoImmunity (Norway)
-Quantoom biosciences (Belgium)
-Stichting Biomedical Primate Research Center (Netherlands)
-University of New South Wales (Australia)

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101081028.

bottom of page